{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:48:40Z","timestamp":1792522120281,"version":"4.5.0"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Approval of the vasopressin V2 receptor antagonist tolvaptan\u2014based on the landmark TEMPO 3:4 trial\u2014marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. However, considering the long-term nature of this treatment, as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the European Renal Association (ERA) was the first society-based recommendation on the use of tolvaptan and has served as a widely used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later-stage disease, have added important evidence to the field, as have post hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use.<\/jats:p>","DOI":"10.1093\/ndt\/gfab312","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T20:17:38Z","timestamp":1636489058000},"page":"825-839","source":"Crossref","is-referenced-by-count":127,"title":["An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-0745","authenticated-orcid":false,"given":"Roman-Ulrich","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"Department II of Internal Medicine and Center for Molecular Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"},{"name":"CECAD, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Lianne","family":"Messchendorp","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Birn","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Departments of Clinical Medicine and Biomedicine, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3469-8614","authenticated-orcid":false,"given":"Giovambattista","family":"Capasso","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Vanvitelli University, Naples, Italy"},{"name":"Biogem Institute for Molecular Biology and Genetics, Ariano Irpino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Cornec-Le Gall","sequence":"additional","affiliation":[{"name":"University Brest, Inserm, UMR 1078, GGB, CHU Brest, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3744-4767","authenticated-orcid":false,"given":"Olivier","family":"Devuyst","sequence":"additional","affiliation":[{"name":"Institute of Physiology, University of Zurich, Zurich, Switzerland"},{"name":"Division of Nephrology, UCL Medical School, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albertien","family":"van Eerde","sequence":"additional","affiliation":[{"name":"Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Guirchoun","sequence":"additional","affiliation":[{"name":"Association PolyKystose France (PKD France), Saclay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Harris","sequence":"additional","affiliation":[{"name":"PKD International, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-3571","authenticated-orcid":false,"given":"Ewout J","family":"Hoorn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nine V A M","family":"Knoers","sequence":"additional","affiliation":[{"name":"Department Genetics, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Korst","sequence":"additional","affiliation":[{"name":"PKD Famili\u00e4re Zystennieren e.V., Bensheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djalila","family":"Mekahli","sequence":"additional","affiliation":[{"name":"PKD Research Group, Laboratory of Pediatrics, Department of Development and Regeneration, KU Leuven, Leuven, Belgium"},{"name":"Department of Pediatric Nephrology and Organ Transplantation, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Meur","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hemodialysis and Renal Transplantation, CHU and University of Brest, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-7236","authenticated-orcid":false,"given":"Tom","family":"Nijenhuis","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboudumc Center of Expertise for Rare Kidney Disorders, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7211-5400","authenticated-orcid":false,"given":"Albert C M","family":"Ong","sequence":"additional","affiliation":[{"name":"Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Sheffield, UK"},{"name":"Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Sayer","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Schaefer","sequence":"additional","affiliation":[{"name":"Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Servais","sequence":"additional","affiliation":[{"name":"Nephrology and Transplantation Department, Necker University Hospital, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Tesar","sequence":"additional","affiliation":[{"name":"Department of Nephrology, 1st Faculty of Medicine, General University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8714-2332","authenticated-orcid":false,"given":"Roser","family":"Torra","sequence":"additional","affiliation":[{"name":"Inherited Kidney Diseases Nephrology Department, Fundaci\u00f3 Puigvert Instituto de Investigaciones Biom\u00e9dicas Sant Pau, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"},{"name":"REDINREN, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"2022042423522496300_bib1","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1093\/ckj\/sfy103","article-title":"Management of autosomal-dominant polycystic kidney disease\u2014state-of-the-art","volume":"11","author":"M\u00fcller","year":"2018","journal-title":"Clin Kidney J"},{"key":"2022042423522496300_bib2","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","article-title":"Autosomal dominant polycystic kidney disease: the changing face of clinical management","volume":"385","author":"Ong","year":"2015","journal-title":"Lancet"},{"key":"2022042423522496300_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib5","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"key":"2022042423522496300_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ekir.2020.03.011","article-title":"The NOCTURNE randomized trial comparing 2 tolvaptan formulations","volume":"5","author":"Perrone","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2022042423522496300_bib7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.xkme.2019.11.008","article-title":"Quality of life in autosomal dominant polycystic kidney disease patients treated with tolvaptan","volume":"2","author":"Anderegg","year":"2020","journal-title":"Kidney Med"},{"key":"2022042423522496300_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2022042423522496300_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000502634","article-title":"Comparison of different selection strategies for tolvaptan eligibility among autosomal dominant polycystic kidney disease patients","volume":"50","author":"Wulfmeyer","year":"2019","journal-title":"Am J Nephrol"},{"key":"2022042423522496300_bib10","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"2022042423522496300_bib11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nrneph.2017.180","article-title":"Tolvaptan slows disease progression in late-stage ADPKD","volume":"14","author":"Ong ACM","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2022042423522496300_bib12","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2022042423522496300_bib13","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2022042423522496300_bib14","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2022042423522496300_bib15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2022042423522496300_bib16","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/ndt\/gfx079","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial","volume":"32","author":"Torres","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2022042423522496300_bib17","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.01520218","article-title":"Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease","volume":"13","author":"Edwards","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022042423522496300_bib18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/j.ajkd.2016.08.028","article-title":"Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: secondary analysis from a randomized controlled trial","volume":"69","author":"Casteleijn","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2022042423522496300_bib19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1681\/ASN.2014030297","article-title":"Imaging-based diagnosis of autosomal dominant polycystic kidney disease","volume":"26","author":"Pei","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"2022042423522496300_bib21","doi-asserted-by":"crossref","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry","volume":"4","author":"Spithoven","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2022042423522496300_bib22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000493325","article-title":"Autosomal dominant polycystic kidney disease: clinical assessment of rapid progression","volume":"48","author":"Furlano","year":"2018","journal-title":"Am J Nephrol"},{"key":"2022042423522496300_bib23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00431-019-03384-x","article-title":"Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial","volume":"178","author":"Schaefer","year":"2019","journal-title":"Eur J Pediatr"},{"key":"2022042423522496300_bib24","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2215\/CJN.03650318","article-title":"Kidney function reserve capacity in early and later stage autosomal dominant polycystic kidney disease","volume":"13","author":"Messchendorp","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022042423522496300_bib25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022042423522496300_bib26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib27","doi-asserted-by":"crossref","first-page":"e138724","DOI":"10.1172\/jci.insight.138724","article-title":"The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD","volume":"5","author":"Lavu","year":"2020","journal-title":"JCI Insight"},{"key":"2022042423522496300_bib28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ekir.2019.04.018","article-title":"Intrafamilial variability of ADPKD","volume":"4","author":"Lanktree","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2022042423522496300_bib29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.ajkd.2017.10.023","article-title":"Patterns of kidney function decline in autosomal dominant polycystic kidney disease: a post hoc analysis from the HALT-PKD trials","volume":"71","author":"Brosnahan","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2022042423522496300_bib30","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2018.01.052","article-title":"Linear and nonlinear estimated GFR slopes in ADPKD patients reaching ESRD","volume":"71","author":"Neagu","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2022042423522496300_bib31","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","article-title":"Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease","volume":"95","author":"Yu","year":"2019","journal-title":"Kidney Int"},{"key":"2022042423522496300_bib32","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10157-018-1574-2","article-title":"Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan","volume":"22","author":"Yamaguchi","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2022042423522496300_bib33","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.ajkd.2016.10.021","article-title":"Performance of the CKD-EPI equation to estimate GFR in a longitudinal study of autosomal dominant polycystic kidney disease","volume":"69","author":"Shen","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2022042423522496300_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ckj\/sfx071","article-title":"Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan","volume":"11","author":"M\u00fcller","year":"2018","journal-title":"Clin Kidney J"},{"key":"2022042423522496300_bib35","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1681\/ASN.2013111184","article-title":"Predictors of autosomal dominant polycystic kidney disease progression","volume":"25","author":"Schrier","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-47206-4","article-title":"Prognostic performance of kidney volume measurement for polycystic kidney disease: a comparative study of ellipsoid vs. manual segmentation","volume":"9","author":"Shi","year":"2019","journal-title":"Sci Rep"},{"key":"2022042423522496300_bib38","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1007\/s00330-018-5918-9","article-title":"A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease","volume":"29","author":"Simms","year":"2019","journal-title":"Eur Radiol"},{"key":"2022042423522496300_bib39","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ki.2015.71","article-title":"A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease","volume":"88","author":"Bhutani","year":"2015","journal-title":"Kidney Int"},{"key":"2022042423522496300_bib41","first-page":"337","article-title":"Total kidney volume (TKV) measurements in autosomal dominant polycystic kidney disease (ADPKD) by 3D ultrasound (3D-US) vs. ultrasound ellipsoid (US-EL) [abstract]","volume":"30","author":"Akbari","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneph.2016.135","article-title":"The importance of total kidney volume in evaluating progression of polycystic kidney disease","volume":"12","author":"Grantham","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2022042423522496300_bib43","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib44","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2018121227","article-title":"Soluble urokinase plasminogen activator receptor and decline in kidney function in autosomal dominant polycystic kidney disease","volume":"30","author":"Hayek","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","article-title":"Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease","volume":"96","author":"Gansevoort","year":"2019","journal-title":"Kidney Int"},{"key":"2022042423522496300_bib46","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1681\/ASN.2018050518","article-title":"Mcp1 promotes macrophage-dependent cyst expansion in autosomal dominant polycystic kidney disease","volume":"29","author":"Cassini","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib47","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000502999","article-title":"Rapid progression of autosomal dominant polycystic kidney disease: urinary biomarkers as predictors","volume":"50","author":"Messchendorp","year":"2019","journal-title":"Am J Nephrol"},{"key":"2022042423522496300_bib48","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.kint.2020.02.008","article-title":"Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease","volume":"98","author":"Magayr","year":"2020","journal-title":"Kidney Int"},{"key":"2022042423522496300_bib49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/bs.mcb.2019.04.014","article-title":"Urinary extracellular vesicles as a source of biomarkers reflecting renal cellular biology in human disease","volume":"154","author":"Braun","year":"2019","journal-title":"Methods Cell Biol"},{"key":"2022042423522496300_bib50","doi-asserted-by":"crossref","first-page":"e12026","DOI":"10.1002\/jev2.12026","article-title":"The proteomic landscape of small urinary extracellular vesicles during kidney transplantation","volume":"10","author":"Braun","year":"2020","journal-title":"J Extracell Vesic"},{"key":"2022042423522496300_bib51","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1681\/ASN.2015090994","article-title":"Proteomics of urinary vesicles links plakins and complement to polycystic kidney disease","volume":"27","author":"Salih","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib52","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.kint.2017.03.026","article-title":"Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease","volume":"92","author":"Kline","year":"2017","journal-title":"Kidney Int"},{"key":"2022042423522496300_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/RLI.0000000000000633","article-title":"Magnetic resonance kidney parenchyma-T2 as a novel imaging biomarker for autosomal dominant polycystic kidney disease","volume":"55","author":"Siedek","year":"2020","journal-title":"Invest Radiol"},{"key":"2022042423522496300_bib54","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022042423522496300_bib55","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ki.2012.225","article-title":"Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation","volume":"82","author":"Ho","year":"2012","journal-title":"Kidney Int"},{"key":"2022042423522496300_bib56","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/HJH.0000000000002776","article-title":"Sodium\u2013glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun","volume":"39","author":"Sarafidis","year":"2021","journal-title":"J Hypertens"},{"key":"2022042423522496300_bib57","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jcph.880","article-title":"Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial","volume":"57","author":"Shoaf","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2022042423522496300_bib58","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ekir.2020.04.014","article-title":"No change in nocturia after NOCTURNE","volume":"5","author":"Meijer","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2022042423522496300_bib59","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf"},{"key":"2022042423522496300_bib60","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2018.09.016","article-title":"Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan","volume":"73","author":"Kramers","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2022042423522496300_bib61","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ekir.2019.09.002","article-title":"Role of liver transplantation in tolvaptan-associated acute liver failure","volume":"4","author":"Endo","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2022042423522496300_bib62","author":"European Medicines Agency"},{"key":"2022042423522496300_bib63","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.kint.2020.04.053","article-title":"Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease","volume":"98","author":"Kramers","year":"2020","journal-title":"Kidney Int"},{"key":"2022042423522496300_bib64","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","article-title":"Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease","volume":"91","author":"Torres","year":"2017","journal-title":"Kidney Int"},{"key":"2022042423522496300_bib65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12882-018-0957-7","article-title":"Case report: a thiazide diuretic to treat polyuria induced by tolvaptan","volume":"19","author":"Kramers","year":"2018","journal-title":"BMC Nephrol"},{"key":"2022042423522496300_bib66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/FJC.0b013e318074f934","article-title":"Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide","volume":"50","author":"Shoaf","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022042423522496300_bib67","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2215\/CJN.04180609","article-title":"A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease","volume":"5","author":"Barash","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022042423522496300_bib68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2215\/CJN.03950510","article-title":"Water prescription in autosomal dominant polycystic kidney disease: a pilot study","volume":"6","author":"Wang","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022042423522496300_bib69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000463063","article-title":"Polycystic kidney disease and the vasopressin pathway","volume":"70","author":"van Gastel","year":"2017","journal-title":"Ann Nutr Metab"},{"key":"2022042423522496300_bib70","doi-asserted-by":"crossref","first-page":"109649","DOI":"10.1016\/j.cellsig.2020.109649","article-title":"Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling","volume":"72","author":"Sussman","year":"2020","journal-title":"Cell Signal"},{"key":"2022042423522496300_bib71","doi-asserted-by":"crossref","first-page":"e018794","DOI":"10.1136\/bmjopen-2017-018794","article-title":"Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD)","volume":"8","author":"Wong","year":"2018","journal-title":"BMJ Open"},{"key":"2022042423522496300_bib72","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","article-title":"Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function","volume":"65","author":"Boertien","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2022042423522496300_bib73","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.ajkd.2013.09.017","article-title":"Dysnatremias in patients with kidney disease","volume":"63","author":"Combs","year":"2014","journal-title":"Am J Kidney Dis"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfab312\/43326292\/gfab312.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/5\/825\/43389940\/gfab312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/5\/825\/43389940\/gfab312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T12:18:44Z","timestamp":1699791524000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/37\/5\/825\/6431643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":73,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,11,19]]},"published-print":{"date-parts":[[2022,4,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfab312","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5]]},"published":{"date-parts":[[2021,11,19]]}}}